Xenon Treatment for Brain Injury After Aneurysmal SAH
Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage
Recruiting
Phase 2
Interventional Study
Subarachnoid Hemorrhage, Aneurysmal
Cerebral Injury
Cerebral Ischemia
Cerebral Infarction
Cardiac Event
Cardiac Failure
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 160 (estimated)
- Sponsor
- Turku University Hospital · Government
Who this trial is looking for
This trial is looking for patients who have suffered an aneurysmal subarachnoid hemorrhage (SAH). Participants will receive either standard care or xenon inhalation for 24 hours to see if it helps protect the brain.
Are You a Good Fit for This Trial?
You may be able to join if
- I have been diagnosed with aneurysmal subarachnoid hemorrhage.
- I am 18 years or older.
- I have signed consent from my next of kin or legal representative.
- My consciousness has deteriorated to a Hunt-Hess score of 3-5.
- I am intubated.
- I have a Glasgow Coma Scale (GCS) score of 3-12.
- Xenon treatment can start within 6 hours after my SAH symptoms began.
You may not be able to join if
- I have had a recent traumatic brain injury.
- I have a large intracerebral hemorrhage over 2.5 cm.
- I have pneumothorax or pneumomediastinum.
- I need more than 60% oxygen support.
- My blood pressure has been too low for over 30 minutes.
- I have fixed and dilated pupils.
- I am pregnant or breastfeeding.
- I have a life-threatening illness.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
An investigator-initiated clinical drug study
Main Objective:
To explore neuroprotective properties of xenon in patients after aneurysmal subarachnoid hemorrhage (SAH).
Primary endpoint: Global fractional anisotropy of white matter of diffusion tensor imaging (DTI). Hypothesis: White matter damage is less severe in xenon treated patients, i.e. global fractional anisotropy is significantly highe…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
To be considered eligible to participate in this study, a SAH subject must meet the inclusion criteria listed below:
1. Informed consent obtained from the next of kin or legal representative
2. Aneurysmal subarachnoid hemorrhage visible on CTA or DSA.
3. Deterioration of consci…
Contacts